Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 16:15 ET | Source: Rocket Lab Corporation

Rocket Lab Receives Regulatory Approval to Acquire Mynaric

Rocket Lab has received regulatory approval to acquire Mynaric, a leading provider of laser optical communications terminals for air, space, and mobile.
March 30, 2026 12:41 ET | Source: CREDIT AGRICOLE NORD DE FRANCE

CREDIT AGRICOLE NORD DE FRANCE : Le Crédit Agricole Nord de France & CITYA IMMOBILIER (Groupe ARCHE)

COMMUNIQUE DE PRESSE Lille, le 30 mars 2026 Le Crédit Agricole Nord de France & CITYA IMMOBILIER (Groupe ARCHE) La banque mutualiste cède à CITYA IMMOBILIER (Groupe ARCHE) l’intégralité de ses...
March 30, 2026 11:45 ET | Source: CREDIT AGRICOLE SA

CREDIT AGRICOLE SA : Programme de rachat d’actions dans le cadre de l’attribution d’actions gratuites

Montrouge, le 30 mars 2026 Programme de rachat d’actions dans le cadre de l’attribution d’actions gratuites Déclaration des transactions sur actions propres réalisées du 26 mars 2026 au 27 mars 2026 ...
March 30, 2026 10:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Dental Laboratories Market Set to Reach USD 13.09 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, March 30, 2026 (GLOBE NEWSWIRE) -- The global dental laboratories market, valued at US$8.66 billion in 2024, stood at US$9.20 billion in 2025 and is projected to advance at a...
March 30, 2026 08:21 ET | Source: SNS Insider pvt ltd

Chemotherapy Market to Hit $20.99 Billion by 2035, Driven by Rising Cancer Incidence – SNS Insider

Austin, United States, March 30, 2026 (GLOBE NEWSWIRE) -- Chemotherapy Market Size & Growth Analysis: According to SNS Insider, the Chemotherapy Market was valued at $10.14 billion in 2025,...
March 30, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...
March 30, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...
March 30, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
March 30, 2026 07:36 ET | Source: Wisekey International Holding Ltd.

WISeKey’s WISeSat.Space Subsidiary Successfully Launches Its 21st Satellite to Low Earth Orbit with SpaceX

WISeKey’s WISeSat.Space Subsidiary Successfully Launches Its 21st Satellite to Low Earth Orbit with SpaceX WISeSat 4.0 Joins SpaceX Transporter-16 Rideshare Mission Deploying Over 100 Satellites,...
March 30, 2026 07:00 ET | Source: Seer, Inc.

Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of...